Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HELEN-001): results from a multicenter, randomized controlled, open-label phase II trialZhenzhen Liu, Xiuchun Chen, Jianghua Qiao et al.|Research Square|2024Cited by 0